| Source: |
| Type: |
| Tumor cell proliferation is a key characteristic of cancer. It refers to the rapid and uncontrolled growth of cells that can lead to the formation of tumors. |
| 6919- | FIS, | Inhibition of c-Jun N-terminal kinase and nuclear factor κ B pathways mediates fisetin-exerted anti-inflammatory activity in lipopolysccharide-treated RAW264.7 cells |
| 6902- | FIS, | Fisetin, a dietary flavonoid, induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cells |
| - | in-vitro, | Bladder, | T24/HTB-9 |
| 2860- | FIS, | Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | Nor, | hTERT-HPNE | - | in-vivo, | NA, | NA |
| 2824- | FIS, | Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics |
| - | Review, | Var, | NA |
| 2829- | FIS, | Fisetin: An anticancer perspective |
| - | Review, | Var, | NA |
| 2830- | FIS, | Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent |
| - | Review, | Var, | NA |
| 2840- | FIS, | Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells |
| - | NA, | CCA, | NA |
| 6990- | Form, | Formononetin induces apoptosis of human osteosarcoma cell line U2OS by regulating the expression of Bcl-2, Bax and MiR-375 in vitro and in vivo |
| - | vitro+vivo, | OS, | U2OS |
| 6980- | Form, | The potential role of formononetin in cancer treatment: An updated review |
| - | Review, | Var, | NA |
| 6981- | Form, | Formononetin: a review of its source, pharmacology, drug combination, toxicity, derivatives, and drug delivery systems |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | PSA, | NA |
| 6982- | Form, | Formononetin: A Review of Its Anticancer Potentials and Mechanisms |
| - | Review, | Var, | NA |
| 6991- | Form, | Formononetin-induced apoptosis of human prostate cancer cells through ERK1/2 mitogen-activated protein kinase inactivation |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 6996- | Form, | MET, | Formononetin and metformin act synergistically to inhibit growth of MCF-7 breast cancer cells in vitro |
| - | in-vitro, | BC, | MCF7 |
| 6976- | Form, | Study on the Mechanism of Formononetin Against Hepatocellular Carcinoma: Regulating Metabolic Pathways of Ferroptosis and Cell Cycle |
| - | vitro+vivo, | HCC, | HepG2 |
| 6963- | Form, | Formononetin-induced apoptosis by activation of Ras/p38 mitogen-activated protein kinase in estrogen receptor-positive human breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | T47D |
| 6964- | Form, | Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo |
| - | vitro+vivo, | BC, | MCF7 |
| 6965- | Form, | Formononetin inhibits colon carcinoma cell growth and invasion by microRNA‑149‑mediated EphB3 downregulation and inhibition of PI3K/AKT and STAT3 signaling pathways |
| - | in-vitro, | CRC, | HCT116 |
| 6973- | Form, | Formononetin enhances the chemosensitivity of triple negative breast cancer via BTB domain and CNC homolog 1-mediated mitophagy pathways |
| - | Human, | BC, | NA |
| 6975- | Form, | Formononetin inhibits colorectal cancer via the miR-490-3p/ABCC2 axis and synergizes with 5-fluorouracil: mechanistic insights and therapeutic implications |
| - | vitro+vivo, | CRC, | NA |
| 7010- | Fuc, | Fucoidan enhances the effect of chemotherapeutic drug against drug-resistant lung cancer cells |
| - | in-vitro, | Lung, | NA |
| 7011- | Fuc, | ATO, | VitA,RetA, | Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo |
| - | NA, | APL, | APL NB4 | - | vitro+vivo, | NA, | NA |
| 7019- | Fuc, | Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43 |
| - | vitro+vivo, | HCC, | HUH7 |
| 7006- | Fuc, | Seaweeds in the Oncology Arena: Anti-Cancer Potential of Fucoidan as a Drug—A Review |
| - | Review, | Var, | NA |
| 1039- | Fuc, | Anti-Proliferative and Pro-Apoptotic vLMW Fucoidan Formulas Decrease PD-L1 Surface Expression in EBV Latency III and DLBCL Tumoral B-Cells by Decreasing Actin Network |
| - | in-vitro, | NA, | NA |
| 4028- | FulvicA, | Mineral pitch induces apoptosis and inhibits proliferation via modulating reactive oxygen species in hepatic cancer cells |
| - | in-vitro, | Liver, | HUH7 |
| 1091- | GA, | Gallic acid reduces cell viability, proliferation, invasion and angiogenesis in human cervical cancer cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Cerv, | HTB-35 |
| 1115- | GA, | Gallic acid alleviates gastric precancerous lesions through inhibition of epithelial mesenchymal transition via Wnt/β-catenin signaling pathway |
| - | in-vivo, | GC, | GES-1 |
| 7041- | GA, | Gallic acid suppresses the progression of clear cell renal cell carcinoma through inducing autophagy via the PI3K/Akt/Atg16L1 signaling pathway |
| - | vitro+vivo, | RCC, | 786-O | - | in-vitro, | RCC, | ACHN | - | in-vitro, | Nor, | HK-2 |
| 7037- | GA, | Chit, | Gallic acid-loaded chitosan nanoparticles enhance the DNA damage and apoptotic features through inhibiting flap endonuclease-1 in triple-negative breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 7042- | GA, | Gallic acid reduces cell growth by induction of apoptosis and reduction of IL-8 in HepG2 cells |
| - | in-vitro, | Liver, | HepG2 |
| 7044- | GA, | QC, | Inhibitory effects of gallic acid and quercetin on UDP-glucose dehydrogenase activity |
| - | in-vitro, | BC, | MCF7 |
| 7046- | GA, | Gallic acid: A promising anti-non-small cell lung cancer compound targeting early growth response protein-1 for apoptosis and ferroptosis |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | NSCLC, | H1299 |
| - | in-vitro, | NSCLC, | A549 |
| 7031- | GA, | Cisplatin, | Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in non‑small cell lung cancer A549 cells via the JAK/STAT3 signaling pathway |
| - | in-vitro, | Lung, | A549 |
| 935- | Gallo, | Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 7051- | Gallo, | MET, | Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells |
| - | in-vitro, | PC, | MIA PaCa-2 |
| 7053- | Gallo, | Therapeutic Strategies Toward Lactate Dehydrogenase Within the Tumor Microenvironment of Pancreatic Cancer |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | Bxpc-3 |
| 5207- | Gallo, | Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism |
| 5206- | Gallo, | Galloflavin prevents the binding of lactate dehydrogenase A to single stranded DNA and inhibits RNA synthesis in cultured cells |
| - | in-vitro, | Var, | NA |
| 5151- | GamB, | Gambogic acid affects ESCC progression through regulation of PI3K/AKT/mTOR signal pathway |
| - | in-vitro, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | KYSE450 |
| 2060- | GamB, | Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells |
| - | in-vitro, | Pca, | NA |
| 1957- | GamB, | Nanoscale Features of Gambogic Acid Induced ROS-Dependent Apoptosis in Esophageal Cancer Cells Imaged by Atomic Force Microscopy |
| - | in-vitro, | ESCC, | EC9706 |
| 1958- | GamB, | Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells |
| - | in-vitro, | Pca, | NA | - | in-vivo, | NA, | NA |
| 7066- | GamB, | Unravelling the Therapeutic Potential of Gambogic Acid: Deciphering Its Molecular Mechanism of Action and Emerging Role as an Anticancer Xanthone |
| - | Review, | Var, | NA |
| 7060- | GamB, | New targets for the antitumor activity of gambogic acid in hematologic malignancies |
| - | Review, | Melanoma, | RPMI-8226 |
| 7059- | GamB, | Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells |
| - | in-vitro, | CRC, | HCT15 |
| 7088- | GAR, | Garcinol inhibits tumour cell proliferation, angiogenesis, cell cycle progression and induces apoptosis via NF-κB inhibition in oral cancer |
| - | in-vitro, | SCC, | SCC4 |
| 7087- | GAR, | Garcinol as an Epigenetic Modulator: Mechanisms of Anti-Cancer Activity and Therapeutic Potential |
| - | Review, | Var, | NA |
| - | in-vivo, | Nor, | NA |
| 7091- | GAR, | Garcinol-A Natural Histone Acetyltransferase Inhibitor and New Anti-Cancer Epigenetic Drug |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:327 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid